{"disease":{"id":"primary-hyperoxaluria-type-1","name":"primary hyperoxaluria type 1","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":2},"drugs":{"marketed":[{"drug_id":"nedosiran","indication_name":"primary hyperoxaluria type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rivfloza","generic_name":"NEDOSIRAN","company_name":"Novo","drug_phase":"marketed","molecular_target":"LDHA mRNA","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Nedosiran, a GalNAc-conjugated siRNA, binds to ASGPR on hepatocytes, degrades LDHA mRNA, reducing hepatic LDH and oxalate production."},{"drug_id":"nedosiran","indication_name":"primary hyperoxaluria type 1","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rivfloza","generic_name":"NEDOSIRAN","company_name":"Novo","drug_phase":"marketed","molecular_target":"LDHA mRNA","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Nedosiran, a GalNAc-conjugated siRNA, binds to ASGPR on hepatocytes, degrades LDHA mRNA, reducing hepatic LDH and oxalate production."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT04982393","title":"BONAPH1DE, A Prospective Observational Study of Patients With Primary Hyperoxaluria Type 1 (PH1)","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":207,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false},{"nct_id":"NCT03067142","title":"Proteomics of Primary Hyperoxaluria Type 1","phase":"","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Ann & Robert H Lurie Children's Hospital of Chicago","has_results":false},{"nct_id":"NCT04042402","title":"Long Term Extension Study in Patients With Primary Hyperoxaluria","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT02706886","title":"Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT02795325","title":"A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":41,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT03681184","title":"A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03847909","title":"A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"Novo Nordisk A/S","has_results":true},{"nct_id":"NCT04580420","title":"Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":28,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false},{"nct_id":"NCT05001269","title":"Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":true},{"nct_id":"NCT04152200","title":"A Study to Evaluate Lumasiran in Patients With Advanced Primary Hyperoxaluria Type 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT03905694","title":"A Study of Lumasiran in Infants and Young Children With Primary Hyperoxaluria Type 1","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":true},{"nct_id":"NCT05993416","title":"Treatment of Primary Hyperoxaluria Type 1 With Nedosiran","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}